In the first four months of 2023, the biopharmaceutical industry has announced several high-value mergers and acquisitions (M&A), primarily in oncology and immunology. In 2022, there were life sciences 258 deals (-30% from 2021) totaling $158.5B (-41% from 2021). While some key industry participants are focusing on expanding core assets, other acquisitions expand capabilities in therapeutic areas where companies do not have existing products.
Read the full article: Life Science Investments Signal a Continued Focus on Oncology and Immunology //
Source: https://www.trillianthealth.com/insights/the-compass/life-science-investments-signal-a-continued-focus-on-oncology-and-immunology